Eptifibatide is a synthetic cyclic heptapeptide that functions as a glycoprotein IIb/IIIa receptor antagonist, specifically designed to inhibit platelet aggregation in the treatment of acute coronary syndromes.… Read more
![Chemical structure of 2-((3R,11R,17S,20S,25aS)-20-((1H-Indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-yl)acetic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2-3R11R17S20S25aS-20-1H-Indol-3-ylmethyl-3-carbamoyl-11-4-guanidinobutyl-1912151821-hexaoxodocosahydro-7H-pyrrolo21-g12dithia5811141720hexaazacyclotri.png&w=3840&q=75)








Eptifibatide is a synthetic cyclic heptapeptide that functions as a glycoprotein IIb/IIIa receptor antagonist, specifically designed to inhibit platelet aggregation in the treatment of acute coronary syndromes. This category provides a comprehensive collection of analytical tools required for the development and testing of this therapeutic agent. Laboratories utilize these high-quality reference standards, including pharmacopeial and non-pharmacopeial impurities, deamidated forms, and dimers, to conduct rigorous impurity profiling and method validation. By incorporating these related compounds and stable isotope labelled standards into their workflows, researchers ensure accurate quantitative analysis and quality control throughout the drug manufacturing lifecycle. These materials facilitate precise identification and monitoring of degradation products and process-related substances, supporting compliance with regulatory standards for pharmaceutical purity and efficacy.